US FTC's Chopra criticizes agency's approach to pharmaceutical mergers
MLex Summary: US Federal Trade Commission member Rohit Chopra said the agency’s pro-merger approach to the pharmaceutical industry isn't sensible and FTC lacks a sound empirical basis for assuming that mergers...To view the full article, register now.
Already a subscriber? Click here to view full article